GC
IMVT icon

Guggenheim Capital’s Immunovant IMVT Stock Holding History

Guggenheim Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Sell
11,165
-1,217
-10% -$37.1K ﹤0.01% 1356
2026
Q1 		$308K Buy
12,382
+122
+1% +$3.16K ﹤0.01% 1374
2025
Q4 		$312K Sell
12,260
-27,185
-69% -$606K ﹤0.01% 1508
2025
Q3 		$636K Sell
39,445
-2,056
-5% -$33.3K ﹤0.01% 1088
2025
Q2 		$664K Sell
41,501
-471
-1% -$7.12K 0.01% 1045
2025
Q1 		$717K Buy
41,972
+5,055
+14% +$106K 0.01% 1032
2024
Q4 		$914K Buy
36,917
+188
+0.5% +$5.33K 0.01% 956
2024
Q3 		$1.05M Sell
36,729
-809
-2% -$23.9K 0.01% 1077
2024
Q2 		$991K Buy
37,538
+3,311
+10% +$94.2K 0.01% 1121
2024
Q1 		$1.11M Buy
34,227
+6,352
+23% +$232K 0.01% 1142
2023
Q4 		$1.17M Buy
+27,875
New +$1.03M 0.01% 1071

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Guggenheim Capital's IMVT Position: Q2 2026 in Review

Guggenheim Capital reduced its Immunovant (IMVT) stake by 9.8% in Q2 2026, selling an estimated $37.1K and leaving 11,165 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

Guggenheim Capital first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.17M in Q4 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Guggenheim Capital held 11,165 shares of Immunovant worth $430K as of Q2 2026.
  • Guggenheim Capital sold 1,217 Immunovant shares in Q2 2026, an estimated $37.1K.
  • Immunovant made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1356 holding.
  • Guggenheim Capital first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • Guggenheim Capital's Immunovant position peaked at $1.17M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.